Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period

No data on real-life experiences of risankizumab efficacy and safety are reported, apart from two isolated case reports. We carried out a single-centre, prospective study to assess the efficacy and safety of risankizumab. Fourteen patients were included (mean age 44.5 +/- 14.2 years). Mean PASI decreased from 12.3 +/- 5.2 (baseline) to 4.4 +/- 2.7 at week 4 (p < 0.01), and to 2.7 +/- 1.7 at week 16 (p < 0.001). A similar trend was observed for BSA. In patients previously treated with biologics (71.4%, n = 10) versus the naive ones, mean baseline PASI was similar (12.7 +/- 5.8 vs 11.3 +/- 3.8). Mean BSA was higher in multifailure (23.5 +/- 11.8 vs 15.5 +/- 11.8). At 4 and 16 weeks, a significant improvement in PASI and BSA was observed in both groups. An improvement in NAPSI score, mean scalp, and palmo-plantar area reduction was noticed during follow-up. No AEs were reported up to week 16 and few and mild grade laboratory tests were reported. Our initial data confirm the promising results on efficacy and safety of Risankizumab, even in a more challenging and real population, composed of a high percentage of multi-failure psoriatic patients who have benefitted from a new class agent.

Automated summary

Efficacy and safety of risankizumab were confirmed in the treatment of psoriasis, with significant improvements observed in both PASI and BSA, even in a challenging population of patients with multiple treatment failures.